Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3]. The gene discussed is KRAS; the disease is colorectal cancer.